Horizon's Genmab drug gets blockbuster status

After the first nine months of 2021, sales of Tepezza have crossed the important USD 1bn annual sales threshold.

Rare eye disease Graves' opthalmopathy has been a big money maker for Horizon Therapeutics. | Photo: Marijan Murat/AP/Ritzau Scanpix

Horizon therapeutics has sold more than twice as much of its drug Tepezza during the first nine months of 2021 than it did during the same period last year, its Q3 report reveals.

This strong growth means that the company has now fulfilled its ambition of making Tepezza a blockbuster drug in 2021. Q3 sales alone totaled USD 610m, bringing sales for the first nine months of the year up to USD 1072m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs